Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Research Library

TIRZ GLP-2 research

6 articles to explore, with links to 8 original sources.

About TIRZ GLP-2

TIRZ is the catalog name for tirzepatide, a peptide investigated at GIP and GLP-1 receptors.

Understand the science

  • How a pragmatic trial studies tirzepatide in everyday care

    Tirzepatide is a GIP and GLP-1 receptor agonist peptide. The “GLP-2” in this catalog label does not identify a receptor it activates. In 2026, the SURMOUNT-REAL UK investigators published a plan to assess how offering tirzepatide would affect outcomes in a routine primary care setting.

    2 sources (2022, 2026)

Explore study findings

  • What the lowest recorded weight adds to a three-year analysis

    Tirzepatide acts at GIP and GLP-1 receptors. The “TIRZ GLP-2” catalog wording refers to tirzepatide rather than the GLP-2 receptor. A 2026 analysis explored how much weight participants regained from their lowest recorded weight while they remained in a long-term study.

    2 sources (2022, 2026)

  • What researchers observed after tirzepatide withdrawal

    Tirzepatide is a GIP and GLP-1 receptor agonist peptide. The “TIRZ GLP-2” label identifies the catalog entry. In a later analysis of SURMOUNT-4, researchers examined how weight regain after withdrawal related to changes in blood pressure, waist circumference and other measures.

    2 sources (2022, 2025)

Check methods and identity

Interpret the evidence

  • Why an early weight response did not tell the whole story

    Tirzepatide is a peptide that activates GIP and GLP-1 receptors. “TIRZ GLP-2” is the catalog’s wording for this molecule. A 2026 analysis asked how participants’ early weight changes related to their outcomes at a later visit.

    2 sources (2022, 2026)

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice.